Ulixertinib

Drug Profile

Ulixertinib

Alternative Names: BVD-523; BVD-ERK; BVD-ERK/HM; BVD-ERK/ST; VRT-0752271; VRT-752271; VX-271

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer BioMed Valley Discoveries
  • Class Aminopyridines; Antineoplastics; Pyrroles; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes
  • Phase I Pancreatic cancer

Most Recent Events

  • 15 Jul 2017 BioMed Valley Discoveries completes a phase I/II trial in Acute myeloid leukaemia (Second-line therapy or greater) and Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO) (NCT02296242)
  • 15 May 2017 BioMed Valley Discoveries completes a phase I pharmacokinetic trial in Healthy volunteers in USA (PO) (NCT02994732)
  • 13 Dec 2016 BioMed Valley Discoveries plans a phase I pharmacokinetic trial in Healthy volunteers in USA (PO) (NCT02994732)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top